2025-01-012025-12-312025-12-31false11097438CES MEDICAL LTD2026-05-0386220falseiso4217:GBPxbrli:pure110974382024-12-31110974382025-12-31110974382025-01-012025-12-31110974382023-12-31110974382024-12-31110974382024-01-012024-12-3111097438bus:SmallEntities2025-01-012025-12-3111097438bus:AuditExempt-NoAccountantsReport2025-01-012025-12-3111097438bus:FullAccounts2025-01-012025-12-3111097438bus:PrivateLimitedCompanyLtd2025-01-012025-12-3111097438core:WithinOneYear2025-12-3111097438core:AfterOneYear2025-12-3111097438core:WithinOneYear2024-12-3111097438core:AfterOneYear2024-12-3111097438core:ShareCapital2025-12-3111097438core:SharePremium2025-12-3111097438core:RevaluationReserve2025-12-3111097438core:OtherReservesSubtotal2025-12-3111097438core:RetainedEarningsAccumulatedLosses2025-12-3111097438core:ShareCapital2024-12-3111097438core:SharePremium2024-12-3111097438core:RevaluationReserve2024-12-3111097438core:OtherReservesSubtotal2024-12-3111097438core:RetainedEarningsAccumulatedLosses2024-12-3111097438core:LandBuildings2025-12-3111097438core:PlantMachinery2025-12-3111097438core:Vehicles2025-12-3111097438core:FurnitureFittings2025-12-3111097438core:OfficeEquipment2025-12-3111097438core:NetGoodwill2025-12-3111097438core:IntangibleAssetsOtherThanGoodwill2025-12-3111097438core:ListedExchangeTraded2025-12-3111097438core:UnlistedNon-exchangeTraded2025-12-3111097438core:LandBuildings2024-12-3111097438core:PlantMachinery2024-12-3111097438core:Vehicles2024-12-3111097438core:FurnitureFittings2024-12-3111097438core:OfficeEquipment2024-12-3111097438core:NetGoodwill2024-12-3111097438core:IntangibleAssetsOtherThanGoodwill2024-12-3111097438core:ListedExchangeTraded2024-12-3111097438core:UnlistedNon-exchangeTraded2024-12-3111097438core:LandBuildings2025-01-012025-12-3111097438core:PlantMachinery2025-01-012025-12-3111097438core:Vehicles2025-01-012025-12-3111097438core:FurnitureFittings2025-01-012025-12-3111097438core:OfficeEquipment2025-01-012025-12-3111097438core:NetGoodwill2025-01-012025-12-3111097438core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3111097438core:ListedExchangeTraded2025-01-012025-12-3111097438core:UnlistedNon-exchangeTraded2025-01-012025-12-3111097438core:MoreThanFiveYears2025-01-012025-12-3111097438core:Non-currentFinancialInstruments2025-12-3111097438core:Non-currentFinancialInstruments2024-12-3111097438dpl:CostSales2025-01-012025-12-3111097438dpl:DistributionCosts2025-01-012025-12-3111097438core:LandBuildings2025-01-012025-12-3111097438core:PlantMachinery2025-01-012025-12-3111097438core:Vehicles2025-01-012025-12-3111097438core:FurnitureFittings2025-01-012025-12-3111097438core:OfficeEquipment2025-01-012025-12-3111097438dpl:AdministrativeExpenses2025-01-012025-12-3111097438core:NetGoodwill2025-01-012025-12-3111097438core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3111097438dpl:GroupUndertakings2025-01-012025-12-3111097438dpl:ParticipatingInterests2025-01-012025-12-3111097438dpl:GroupUndertakingscore:ListedExchangeTraded2025-01-012025-12-3111097438core:ListedExchangeTraded2025-01-012025-12-3111097438dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-01-012025-12-3111097438core:UnlistedNon-exchangeTraded2025-01-012025-12-3111097438dpl:CostSales2024-01-012024-12-3111097438dpl:DistributionCosts2024-01-012024-12-3111097438core:LandBuildings2024-01-012024-12-3111097438core:PlantMachinery2024-01-012024-12-3111097438core:Vehicles2024-01-012024-12-3111097438core:FurnitureFittings2024-01-012024-12-3111097438core:OfficeEquipment2024-01-012024-12-3111097438dpl:AdministrativeExpenses2024-01-012024-12-3111097438core:NetGoodwill2024-01-012024-12-3111097438core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3111097438dpl:GroupUndertakings2024-01-012024-12-3111097438dpl:ParticipatingInterests2024-01-012024-12-3111097438dpl:GroupUndertakingscore:ListedExchangeTraded2024-01-012024-12-3111097438core:ListedExchangeTraded2024-01-012024-12-3111097438dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-01-012024-12-3111097438core:UnlistedNon-exchangeTraded2024-01-012024-12-3111097438core:NetGoodwill2025-12-3111097438core:IntangibleAssetsOtherThanGoodwill2025-12-3111097438core:LandBuildings2025-12-3111097438core:PlantMachinery2025-12-3111097438core:Vehicles2025-12-3111097438core:FurnitureFittings2025-12-3111097438core:OfficeEquipment2025-12-3111097438core:AfterOneYear2025-12-3111097438core:WithinOneYear2025-12-3111097438core:ListedExchangeTraded2025-12-3111097438core:UnlistedNon-exchangeTraded2025-12-3111097438core:ShareCapital2025-12-3111097438core:SharePremium2025-12-3111097438core:RevaluationReserve2025-12-3111097438core:OtherReservesSubtotal2025-12-3111097438core:RetainedEarningsAccumulatedLosses2025-12-3111097438core:NetGoodwill2024-12-3111097438core:IntangibleAssetsOtherThanGoodwill2024-12-3111097438core:LandBuildings2024-12-3111097438core:PlantMachinery2024-12-3111097438core:Vehicles2024-12-3111097438core:FurnitureFittings2024-12-3111097438core:OfficeEquipment2024-12-3111097438core:AfterOneYear2024-12-3111097438core:WithinOneYear2024-12-3111097438core:ListedExchangeTraded2024-12-3111097438core:UnlistedNon-exchangeTraded2024-12-3111097438core:ShareCapital2024-12-3111097438core:SharePremium2024-12-3111097438core:RevaluationReserve2024-12-3111097438core:OtherReservesSubtotal2024-12-3111097438core:RetainedEarningsAccumulatedLosses2024-12-3111097438core:NetGoodwill2023-12-3111097438core:IntangibleAssetsOtherThanGoodwill2023-12-3111097438core:LandBuildings2023-12-3111097438core:PlantMachinery2023-12-3111097438core:Vehicles2023-12-3111097438core:FurnitureFittings2023-12-3111097438core:OfficeEquipment2023-12-3111097438core:AfterOneYear2023-12-3111097438core:WithinOneYear2023-12-3111097438core:ListedExchangeTraded2023-12-3111097438core:UnlistedNon-exchangeTraded2023-12-3111097438core:ShareCapital2023-12-3111097438core:SharePremium2023-12-3111097438core:RevaluationReserve2023-12-3111097438core:OtherReservesSubtotal2023-12-3111097438core:RetainedEarningsAccumulatedLosses2023-12-3111097438core:AfterOneYear2025-01-012025-12-3111097438core:WithinOneYear2025-01-012025-12-3111097438core:Non-currentFinancialInstrumentscore:CostValuation2025-01-012025-12-3111097438core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-012025-12-3111097438core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-012025-12-3111097438core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-012025-12-3111097438core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-012025-12-3111097438core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-012025-12-3111097438core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3111097438core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3111097438core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3111097438core:Non-currentFinancialInstrumentscore:CostValuation2025-12-3111097438core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-12-3111097438core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-12-3111097438core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-12-3111097438core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-12-3111097438core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-12-3111097438core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-12-3111097438core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-12-3111097438core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-12-3111097438core:Non-currentFinancialInstrumentscore:CostValuation2024-12-3111097438core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-3111097438core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-3111097438core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-3111097438core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-3111097438core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-3111097438core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-3111097438core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-3111097438core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-3111097438bus:Director12025-01-012025-12-3111097438bus:Director22025-01-012025-12-3111097438bus:Director32025-01-012025-12-3111097438bus:Director42025-01-012025-12-3111097438core:FurnitureFittingsToolsEquipment2024-12-3111097438core:FurnitureFittingsToolsEquipment2025-01-012025-12-3111097438core:FurnitureFittingsToolsEquipment2025-12-31

CES MEDICAL LTD

Registered Number
11097438
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2025

CES MEDICAL LTD
Company Information
for the year from 1 January 2025 to 31 December 2025

Directors

HYSENI, Elion
KOPSACHEILIS, Nikolaos
QURESHI, Kashif Munir-Ud-Din
SHAHID, Syed Mohammed

Registered Address

Maidstone Innovation Centre Gidds Pond Way
Weavering
Maidstone
ME14 5FY

Registered Number

11097438 (England and Wales)
CES MEDICAL LTD
Balance Sheet as at
31 December 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets3283,036260,860
Investments4673,941295,488
956,977556,348
Current assets
Stocks542,000-
Debtors6629,283316,900
Cash at bank and on hand7,179885
678,462317,785
Creditors amounts falling due within one year7(1,430,597)(785,106)
Net current assets (liabilities)(752,135)(467,321)
Total assets less current liabilities204,84289,027
Creditors amounts falling due after one year8(102,625)(119,061)
Net assets102,217(30,034)
Capital and reserves
Called up share capital70100
Other reserves(374,030)-
Profit and loss account476,177(30,134)
Shareholders' funds102,217(30,034)
The financial statements were approved and authorised for issue by the Board of Directors on 3 May 2026, and are signed on its behalf by:
HYSENI, Elion
Director
Registered Company No. 11097438
CES MEDICAL LTD
Notes to the Financial Statements
for the year ended 31 December 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Straight line (years)
Land and buildings10
Plant and machinery4
Fixtures and fittings4
Vehicles4
Office Equipment4
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
Finance leases and hire purchase contracts
Assets held under finance leases which are leases where substantially all the risks and rewards of ownership of the asset have passed to the company, and hire purchase contracts are capitalised in the balance sheet. They are depreciated over the shorter of their useful lives or the term of the lease.
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
2.Average number of employees
This excludes directors

20252024
Average number of employees during the year275
3.Tangible fixed assets

Land & buildings

Plant & machinery

Fixtures & fittings

Office Equipment

Total

£££££
Cost or valuation
At 01 January 2576,715403,674-60,003540,392
Additions-195,0402,436-197,476
Disposals-(270,722)--(270,722)
At 31 December 2576,715327,9922,43660,003467,146
Depreciation and impairment
At 01 January 25-236,574-42,958279,532
Charge for year-72,595--72,595
On disposals-(168,017)--(168,017)
At 31 December 25-141,152-42,958184,110
Net book value
At 31 December 2576,715186,8402,43617,045283,036
At 31 December 2476,715167,100-17,045260,860
4.Fixed asset investments

Investments in groups1

Loans to groups2

Total

£££
Cost or valuation
At 01 January 25100295,388295,488
Additions-378,453378,453
At 31 December 25100673,841673,941
Net book value
At 31 December 25100673,841673,941
At 31 December 24100295,388295,488

Notes

1Investments in group undertakings and participating interests
2Loans to group undertakings and participating interests
5.Stocks

2025

2024

££
Raw materials and consumables42,000-
Total42,000-
6.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables593,314150,449
Other debtors96-
Prepayments and accrued income35,873166,451
Total629,283316,900
7.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables941,397365,896
Bank borrowings and overdrafts402,076269,600
Finance lease and HP contracts14,19456,609
Other creditors7,604-
Accrued liabilities and deferred income65,32693,001
Total1,430,597785,106
8.Creditors: amounts due after one year

2025

2024

££
Other creditors102,625119,061
Total102,625119,061
9.Obligations under finance leases

2025

2024

££
Finance lease and HP contracts116,818175,670